23 of 35 studies reported significant improvements in primary outcomes (e.g. psychotic symptoms, anxiety, seizures), especially in epilepsy (11/11 studies positive); however no positive effects in smaller RCTs in diabetes, Crohn's disease, glaucoma, fatty liver or chronic pain.
Systematic review on CBD dosing across 13 medical contexts; k=35 studies. Epilepsy most frequently studied (k=11 studies, all with positive effects on seizure frequency/severity; average dose 15 mg/kg/d in RCTs). Effective doses across all indications: <1 to 50 mg/kg/d. 23 of 35 studies showed significant improvement in primary outcomes (psychotic symptoms, anxiety, seizures). No positive signal in small RCTs (n=6–62) for diabetes, Crohn's disease, ocular hypertension, fatty liver, chronic pain (low doses ~2,4 mg/kg/d).
The third of four GRADE levels, the effect estimate is probably reliable.
The impediment to action advances action.